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ABSTRACT  
 
Commonly diagnosed at late stage, pancreatic cancer (PC) is a highly fatal cancer with limited 
opportunities for early detection and effective treatment. The identification of modifiable risk 
factors may offer relevant scientific evidence for PC prevention. This doctoral research 
program investigated PC etiology through a comprehensive examination of the role of alcohol 
consumption and other lifestyle determinants in the occurrence of PC within the European 
Prospective Investigation into Cancer and nutrition (EPIC) study, a multi-center cohort 
involving more than 500,000 participants from 10 European countries. 
Alcohol intake was evaluated with respect to the risk of PC. The role of different alcoholic 
beverages and potential effect modification by smoking habits on PC risk were also 
examined. Findings from this evaluation provided epidemiological evidence that large intakes 
of alcohol were associated with an increased risk of PC. 
The association between the healthy lifestyle index, a score combining information on 
smoking history, alcohol intake, diet, obesity, and physical activity and the risk of PC was 
examined. To quantify the impact of modifying several lifestyle factors, population 
attributable fractions were estimated assuming counterfactual scenarios whereby study 
participants hypothetically moved towards healthier behaviors. Adherence to healthy lifestyle 
habits was strongly inversely related to PC. 
This comprehensive evaluation provides informative insights on the etiology of PC and 
supports the development and implementation of public health guidelines to promote 
individuals’ adoption of healthy lifestyle habits for PC prevention. 
 
Keywords: Pancreatic cancer, lifestyle factors, alcohol consumption, smoking, healthy 
lifestyle index, EPIC, population attributable fractions. 
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RESUME  
 
Souvent diagnostiqué à un stade avancé, le cancer du pancréas (CP) est un cancer 
particulièrement létal pour lequel il n’y a, à ce jour, que très peu de possibilités de traitement 
et de diagnostic anticipé. L’identification de facteurs de risque modifiables pourrait fournir 
des données épidémiologiques nécessaires au soutien de la mise en place de mesures 
préventives. Cette thèse a pour but d’étudier l’étiologie du CP en évaluant le rôle de la 
consommation d’alcool et du mode de vie dans l’étude prospective européenne sur le cancer 
et la nutrition (EPIC), cohorte multicentrique de plus de 500,000 sujets provenant de 10 pays 
européens. 
La consommation d’alcool a d’abord été évaluée en regard du risque de CP. Les rôles des 
différents types d’alcools ainsi que du tabagisme dans la relation entre l’alcool et le CP ont été 
examinés. Cette évaluation a montré qu’une consommation d’alcool élevée était associée à 
une augmentation du risque de CP. 
Ensuite, la relation entre le Healthy Lifestyle Index, un indicateur combinant le passé 
tabagique, la consommation d’alcool, l’alimentation, l’anthropométrie et l’activité physique, 
et le risque de CP a été étudiée. Pour quantifier l’impact de l’amélioration de ces facteurs, des 
fractions de CP attribuables ont été estimées en considérant des scénarios hypothétiques où les 
participants adopteraient des modes de vie plus sains. L’adhérence à des habitudes saines était 
fortement et inversement associée au risque de CP. 
Ces travaux ont apporté des connaissances informatives sur l’étiologie du CP, et soutiennent 
le développement de mesures de santé publique promouvant la prévention du CP par 
l’adoption de modes de vie sains. 
 
Mots clefs : cancer du pancréas, facteurs du mode de vie, consommation d’alcool, tabagisme, 
healthy lifestyle index, EPIC, fractions de population attribuables. 
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RESUME SUBTANTIEL  
 
Souvent diagnostiqué à un stade avancé, le cancer du pancréas (CP) est un cancer 
particulièrement létal pour lequel il n’y a, à ce jour, que très peu de possibilités de traitement 
et de diagnostic anticipé. Les études épidémiologiques menées jusqu’à présent ont permis 
d’établir que le tabagisme, la surcharge pondérale et le diabète de type II sont les principaux 
facteurs de risque du CP. Des études récentes ont également suggéré qu’une consommation 
considérable d’alcool pourrait être associée au CP. Les habitudes alimentaires et l’activité 
physique, quant à eux, serraient inversement associés, mais les données épidémiologiques 
actuelles ne convergent pas. L’identification de facteurs de risque modifiables pourrait fournir 
des données épidémiologiques nécessaires au soutien de la mise en place de mesures 
préventives. Cette thèse a pour but d’étudier l’étiologie du CP en évaluant le rôle de la 
consommation d’alcool et du mode de vie dans l’étude prospective européenne sur le cancer 
et la nutrition (EPIC), cohorte multicentrique de plus de 500,000 sujets provenant de 10 pays 
européens. 
La consommation d’alcool a d’abord été évaluée en regard du risque de CP. Bien que l’alcool 
soit un carcinogène reconnu pour le foie, le colon-rectum, le sein et les voies aéro-digestives 
supérieures, les données concernant le pancréas ont été jusque-là limitées par la faible 
incidence du CP, notamment pour dissocier le rôle de l’alcool de celui du tabagisme. Dans 
cette étude, les rôles de la consommation d’alcool au cours de la vie, des différents types 
d’alcools ainsi que celui du tabagisme dans la relation entre l’alcool et le CP ont été examinés. 
Dans la cohorte EPIC, 1,283 cas de CP (dont 57% de femmes) ont été rapportés au cours de 
15 années de suivi. Les quantités d’alcool consommées au cours de la vie et pendant l’année 
précédant le recrutement ont été estimées par un questionnaire de fréquences alimentaires et 
un questionnaire portant sur le mode de vie. Des modèles de Cox à risques proportionnels 
avec l’âge comme échelle de temps ont permis d’estimer des hazard ratios (HR) et leur 
intervalle de confiance à 95% (IC95%). La consommation d’alcool était positivement 
associée au risque de CP chez les hommes. Les associations mesurées étaient principalement 
observées pour les niveaux d’alcool les plus élevés, avec des HRs comparant les grands 
consommateurs (>60g/jour) à la catégorie de référence (0.1-4.9 g/jour) de 1.77 (IC95% : 1.06, 
2.95) pour la consommation d’alcool au cours de la vie, et de 1.63 (1.16, 2.29) pour la 
consommation d’alcool au recrutement. Les consommations de bière (>40 g/jour) et de 
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liqueurs/spiritueux (>10 g/jour) ont montré des HRs de 1.58 (1.07, 2.34) et de 1.41 (1.03, 
1.94) respectivement, par rapport à la catégorie de référence (0.1-2.9 g/jour). Chez les 
femmes, les HRs n’étaient pas statistiquement significatifs. La relation entre l’alcool et le 
risque de CP n’était pas modifiée par le statut tabagique. Cette évaluation a donc montré 
qu’une consommation d’alcool élevée était associée à une augmentation du risque de CP. 
Bien que les habitudes liées au mode de vie aient tendance à être dépendantes les unes des 
autres, les données épidémiologiques concernant l’association combinée de ces différents 
facteurs et leur relation avec l’incidence du CP restent à ce jour limitées, particulièrement en 
Europe. Dans la deuxième partie de ce travail de thèse, le Healthy Lifestyle Index (HLI), un 
score combinant des informations sur le passé tabagique, la consommation d’alcool, 
l’alimentation, l’anthropométrie et l’activité physique, a été étudié en relation avec le risque 
de CP. Deux versions de ce score ont été analysées : le HLIIMC incluant l’indice de masse 
corporelle (IMC) comme mesure de l’adiposité globale et le HLIRTH incluant le rapport taille-
hanche (RTH) comme mesure de l’adiposité centrale. Des modèles de Cox à risques 
proportionnels avec l’âge comme échelle de temps ont permis d’estimer les HR et leur IC95% 
pour une augmentation d’un écart type correspondant à 3 unités de HLI. Comme la relation 
observée pouvait être le résultat de l’action d’un seul des facteurs du HLI, leur rôle dans la 
relation entre le HLI et le CP a été évalué au cours d’analyses de sensibilité excluant à tour de 
rôle chaque composante du score. Pour quantifier l’impact de l’amélioration de ces facteurs, 
des fractions de population attribuables (FPA) ont été estimées en considérant des scénarios 
hypothétiques où les participants adopteraient des modes de vie plus sains. Les HRs étaient de 
0.84 (0.79, 0.89) et de 0.77 (0.72, 0.82), pour un écart type de HLIIMC et de HLIRTH, 
respectivement. L’exclusion du tabagisme du HLIRTH a montré un HR de 0.88 (0.82, 0.94). La 
FPA estimée pour une amélioration de la consommation d’alcool, de la qualité de 
l’alimentation, du RTH et du niveau d’activité physique était de 14% (6%, 21%) et de 19% 
(11%, 26%) si l’amélioration du tabagisme était considérée. L’adhérence à des habitudes 
saines était fortement et inversement associée au risque de CP au-delà du rôle bénéfique de 
l’évitement du tabagisme. 
Les travaux inscrits dans ce projet de thèse ont apporté des connaissances informatives sur 
l’étiologie du CP, et soutiennent le développement de mesures de santé publique promouvant 
sa prévention par l’adoption de modes de vie sains. Les recherches sur les facteurs de risque 
du CP seront poursuivies en s’appuyant sur des projets de plus grande envergure exploitant 
des données d’études poolées. Une collaboration entre le CIRC et l’école de santé publique de 
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Harvard est actuellement en cours. Ce projet a pour but d’étudier les cancers pour lesquels le 
niveau de preuve épidémiologique concernant leur relation avec la consommation d’alcool est 
limité, le CP inclus, en regroupant à l’échelle internationale les données de 36 études 
prospectives. Il permettra notamment d’évaluer la relation parmi les non-fumeurs et les profils 
de consommation d’alcool plus spécifiques, en vue d’étudier des hypothèses 
épidémiologiques jusque-là rarement examinées du fait de la faible occurrence du CP. 
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1. Physiopathology of pancreatic cancer  
The pancreas is a gland of the digestive system involved in both endocrine and exocrine 
metabolic activities (1,2). The endocrine function allows the regulation of the glucose 
homeostasis through hormones secretion (i.e. glucagon and insulin). These hormones are 
secreted by particular cell clusters called the islets of Langerhans which represent 2% of the 
overall pancreatic mass. The exocrine function of the pancreas includes the secretion of 
digestive fluids by acinar cells representing 85% of pancreatic mass. These produced 
pancreatic fluids are drained to the duodenum through different pancreatic ducts (1) (Figure 
1). Common disorders related to the pancreas are pancreatitis, pancreatic cysts, diabetes and 
pancreatic cancer (PC). 
 
Figure 1. Anatomy and histology of the pancreas (Source: Encyclopedia Britannica, Inc.) 
PC can be categorized into exocrine and endocrine types depending on the function of the cell 
from which it arises. Exocrine tumors represent around 95% of PC (3), of which more than 
80% of these exocrine PC are adenocarcinomas and nearly all of them arise from the cells 
lining the pancreatic ducts, thus named pancreatic ductal adenocarcinomas (PDAC). Rarer 
types of exocrine PC tumors include cystic tumors and acinar cells tumors, however, only a 
small proportion of cystic tumors are cancerous. Acinar cells tumors present a slower growing 
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pace than other pancreatic tumors and generally occur at younger age. Both these rarer types 
of exocrine tumor have a better prognosis compared with other exocrine tumors (4).  
A growing body of evidence has helped to establish that invasive adenocarcinoma develops 
from well-defined progression of morphologic entities originating from noninvasive lesions. 
The most common precursor lesion leading to invasive adenocarcinoma is a microscopic 
lesion called the pancreatic intraepithelial neoplasia (PanIN) (5). PanIN lesions originate from 
pancreatic duct cells and progress from PanIN-1 to PanIN-3 morphology, finally transitioning 
to invasive carcinoma when the cancerous ductal cells move to the pancreatic parenchyma. 
The transitions between the different PanIN stages are driven by accumulating genetic and 
epigenetic alterations. Telomere shortening and kRAS mutations appear to be early events in 
transformation from normal epithelium to PanIN-1, while mutations in TP53, BRCA2 and 
SMAD4 mutations are late events in the progression from PanIN-1 to PanIN-3 (Figure 2) (6). 
Eighty percent of these mutations occurring in the development of pancreatic adenocarcinoma 
appear to be sporadic (7). Less frequently, PC adenocarcinoma arise from macroscopic cystic 
precursor lesions including intraductal papillary mucinous neoplasm (IPMN) and mucinous 
cystic neoplasm (MCN) (7–11). Usually diagnosed at early stages within younger 
populations, IPMN and MCN benefit from a better prognosis compared with PanIN (12). 
 
 
Figure 2. Model for pancreatic carcinogenesis displaying progression from normal cells to 
PanIN precursor low grade (PanIN-1 and -2) and high grade (PanIN-3) lesions, invasive 
cancer, and metastatic pancreatic cancer (Source: Chhoda et al., The American Journal of 
Pathology, 2019). 
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Endocrine or neuroendocrine pancreatic tumors are uncommon and account for only 5% of 
PC, with incidence rates below 1 case per 100,000 person-years (PY). Most of these tumors 
are malignant, but slow-growing and have a better prognosis than exocrine tumors (13). 
PC are mostly diagnosed at an advanced stage and more than 80% of cases have already 
spread to a regional or distant stage (14). Early stages of PC tumor development are 
asymptomatic, and when symptoms occur, they are usually non-specific to PC and can be 
attributable to a broad number of diseases, including gastric ulcers, choledochal cysts, 
pancreatitis as well as other gastro intestinal cancers (3,15). To date, treatment approaches in 
patients diagnosed with PC largely consist in palliative care which allows a few months to be 
saved only, even in countries with the most advanced cancer care protocols (7,16).  
 
2. Descriptive epidemiology of pancreatic cancer  
2.1. A rare and fatal cancer worldwide  
PC is the 15th cause of cancer worldwide, with an estimated 458,918 new cases diagnosed in 
2018, accounting for 2.5% of all cancers. This is a rare cancer with an age-standardized 
incidence rate of 4.8 per 100,000 PY (17). Ranked as the 9th deadliest cancer worldwide, in 
2018 PC accounted for 4.5% cancer-related deaths with a total number of 432,242 deaths and 
an age-standardized mortality rate of 4.4 per 100,000 PY (17). With a mortality-incidence 
ratio close to one, PC is one of the most fatal cancers, and it has been recently ranked as the 
3rd leading cause of cancer-related death after lung and colorectal cancers in North America 
and Western Europe populations (17). 
The occurrence of PC differs according to World areas and in 2018 the highest incidence rates 
were observed in Western Europe (8.3 per 100,000 PY), North America (7.6 per 100,000 PY) 
and Central-Eastern Europe (7.5 per 100,000 PY), while the lowest rates were found in South 
Central Asia (1.0 per 100,000 PY), Eastern Africa (1.4 per 100,000 PY) and South-Eastern 
Asia (2.1 per 100,000 PY) (Figure 3) (17). Countries with the highest incidence of PC are 
Hungary (10.8 per 100,000 PY) and Uruguay (10.7 per 100,000 PY), while the lowest 
incidence rates were found in Guinea (0.35 per 100,000 PY) and Malawi (0.40 per 100,000 
PY) (Figure 4) (17). Mortality rates follow almost the same pattern as incidence rates across 
world areas with the highest rates in Western Europe (7.6 per 100,000 PY) and Central-
Eastern Europe (7.3 per 100,000 PY), while the lowest rates were found in South Central Asia 
(1.0 per 100,000 PY) and Eastern Africa (1.4 per 100,000 PY) (Figure 3) (17). As for 
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incidence rates, mortality rates are about 1.8-time higher in men than in women (Figure 5) 
(17). 
 
Figure 3. Estimated age-standardized incidence and mortality rates (per 100,000 person-
years) of pancreatic cancer by World areas in 2018 (both sexes and all ages), ranked by 
incidence rate. The five firt and the five last world areas are displayed (Source: GLOBOCAN 
2018, IARC/WHO) 
 
Figure 4. Estimated age-standardized incidence rates of pancreatic cancer in the World in 
2018 (for both sexes and all ages) (Source: GLOBOCAN 2018, IARC/WHO) 
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It was reported that countries with high level of human development index (HDI) have the 
largest incidence rates of PC (18). Although genetic and lifestyle profiles may account for the 
observed geographic disparities, access to diagnostic tools and health care modalities may 
well influence the chance of identifying PC in these populations. Differences may also be 
attributed to the quality of cancer registries, specifically in terms of coverage, completeness 
and accuracy (15). 
PC occurrence also slightly differs by gender with a higher incidence rate in men (5.5 per 
100,000) than in women (4.0 per 100,000) (17,19). Sex-specific incidence rates by world area 
are presented in the Figure 5. The hypothesis suggesting that reproductive factors could 
influence PC risk by gender have been studied during the last decade (20,21), and differences 
in PC rates between men and women are believed to be due to differences in lifestyle patterns, 
including smoking and obesity, or undiscovered genetic factors (22). 
 
 
Figure 5. Sex-specific incidence and mortality rates of pancreatic cancer by World area 
(Source: GLOBOCAN 2018, IARC/WHO) 
The risk of developing PC increases with age. Almost 90% of cases are diagnosed after 55 
years of age and the highest incidence is reported in individuals aged between 60 and 80 
years, with a median age at diagnosis of 71 years (15,19,23). In the American population, 
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with a mean age at diagnosis of 65 and 67 in men and women, respectively, the age at 
diagnosis is steadily increasing with a continuous trend towards the years of age 80 (24,25). 
Whereas, in India, a country with a pyramidal age structure, the incidence of PC starts to rise 
in the 5th decade, with a peak at age 70 (22,25). 
Survival rates of PC are still very low, even in countries with high HDI (15,17). In 2015, the 
Eurocare-5 Working Group examined data from 29 European countries, and reported a 1-year 
survival rate of 26% and a 5-year survival rates of 7% (26)The United-Kingdom had one of 
the lowest 5-year survival rates in Europe with a rate of 3% in 2011 (27). In US, the survival 
rate was not considerably higher with a rate of 8% in 2018 (25). It has been shown that the 5-
year survival rate can be better when pancreatic tumors are diagnosed at less advanced stage 
of progression with survival rate of 29% in localized tumors, while in tumors spread at 
regional and distant levels the survival rates decreased considerably to 11% and 3%, 
respectively. Other tumor’s characteristics, as well as age at diagnosis, gender, treatment and 
heath care system modalities, preexisting health conditions and lifestyles factors affect PC 
survival (15,27). 
 
2.2. Increasing trends of pancreatic cancer  
In past decades, PC incidence gradually increased worldwide (17), particularly in North 
America, Western Europe, and Oceania for both sexes (19,28). In the last 20 years, the 
greatest increase in incidence occurred in France between 2003-2012 with an average annual 
percentage change of 4.4% and 5.4% in men and women, respectively (28), while in the US 
population, PC incidence has gradually increased over the last 40 years, with an annual 
percentage change of 1.6% between 2000 and 2014 (19,29). Trends of different histologic 
subtypes of pancreatic tumor, extracted from the SEER database, showed that incidence rose 
most rapidly during 1992-2013 for adenocarcinomas (the largest histologic subtype), 
compared with other less common PC subtypes (19). 
As a consequence of these increasing trends in incidence, in contrast to most cancers (14), 
mortality from PC has globally steadily increased over the last 50 years for both men and 
women, especially in Europe, Japan, Brazil, Korea, and US (30,31). Overall no substantial 
changes in PC survival rates have occurred over (15,26). Minor improvement in mortality 
rates have been observed during the last decade in some high income countries from Western 
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Europe, North America and in Japan (29,30), and overall PC prognosis has remained largely 
unchanged worldwide (15,27,30).  
Future temporal trends of PC over the period 2018-2040 were evaluated in GLOBOCAN 
2018 (32). It is expected that PC incidence and mortality will follow an increasing trend, with 
78% more cases and 80% more deaths from PC by 2040 in the World, notably among 
European and American populations, in 2018. The number of deaths by PC are expected to be 
25% higher than the number of deaths due to breast cancer in the European Union by 2025 
(33). In the US population, it is possible that PC could surpass colorectal cancers and become 
the second leading cause of cancer-related death after lung cancer by 2030 (34).  
In absence of major improvement in survival rates, the rise in PC incidence and mortality has 
become a major public health concern (15). Improved diagnostic and death certification of the 
disease might partially explain the increase in PC incidence worldwide (31). Trends of PC 
might partly reflect patterns of tobacco consumption throughout the world and it is likely that 
a level off in incidence and mortality trends observed in high income countries between 1970 
and 1990 might be related to implementation of tobacco control policies (19,30). In the most 
recent decades, the increase in obesity and diabetes prevalence may also partly explain the 
stable or slowly rising PC rates in the Western World (15,19,28,33).  
 
2.3. A rare cancer with a reduced screening effectiveness  
The lack of opportunity of effective treatments for PC is mostly due to late diagnoses. PC 
early detection, prior to invasion, is to date the primary goal of PC screening to improve the 
chance for patients to undergo curative chemotherapy and surgery rather than palliative 
treatments (6). However, despite its aggressiveness and high degree of lethality, PC screening 
is not a standard practice in the general population with the present technologies of diagnosis 
(6,35). Current screening strategies have been so far limited to the clinical follow-up of 
patients already identified as high risk individuals based on family history of PC or 
underlying genetic syndrome, who represent 7% and 3% of PC cases, respectively (12). As a 
result, ongoing approaches target only a small part of the PC burden. In addition, the success 
of screening resides in noninvasive detection of the smallest lesions, but no gold standard 
technic for PC diagnosis has been yet identified, and expensive imaging techniques combined 
with highly invasive endoscopic examination have been so far the most reliable methods of 
diagnosis and staging of the disease (15).  
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Recently, advances in the understanding of the carcinogenic pathways driving progression of 
precursor lesions have shown promising results (35). Progression from PanIN-3 lesion to 
malignant adenocarcinoma would occur in about 12 years (24,36,37), allowing a large time 
window for early detection. The use of blood biomarker for early detection is a fast 
developing new field of research, but current candidate biomarkers are non-specific to PC and 
at present can only be used to confirm a diagnosis, predict a prognosis, or evaluate a 
recurrence after resection (12,38). Additionally, knowledge is so far limited to biopsy 
biomarkers collected in high risk populations undergoing invasive medical examination, and 
biomarkers collected through non-invasive technique in general population are yet to be 
defined (6,15).  
In absence of reliable screening strategies in the general population, primary prevention 
aiming at improving awareness on the management of modifiable lifestyle, and thus the 
quantification of the associations of these modifiable risk factors, is of utmost importance. 
 
3. Etiology of pancreatic cancer  
Over the last decades, the identification of risk factors causally related to the occurrence of 
pancreatic tumors has been a main research priority. Although the knowledge about the 
pathogenesis of pancreatic tumors has greatly improved, PC etiology remains poorly 
understood and only a few risk factors have been consistently causally related to PC 
occurrence.  
 
3.1. Lifestyle and environmental risk factors  
3.1.1. Smoking  
Smoking is one of the major risk factors for PC. In 2004, the International Agency for 
Research on Cancer (IARC) monographs recognized the causal relationship, with a strong 
positive association (39). It has been estimated that tobacco smoking account for 11 to 32 % 
of the total number of PC cases (40). Compared with non-smokers, current smokers have been 
estimated to have a 74% (95%CI: 61%, 87%) higher risk of PC, while weaker increases in 
risk have been observed in former smokers with a 20% (11%, 29%) higher risk, in a meta-
analysis based on 82 independent studies (41). In a more recent meta-analysis of 42 studies, 
where authors reported similar strength of association, the risk of PC was positively 
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associated with the duration of smoking, the number of cigarettes smoked per day and also 
with passive smoking, while it was inversely related with time since smoking cessation (42). 
Cigarette smoking has been hypothesized to generate circulating carcinogens that cause 
pancreatic inflammation and mutations in proto-oncogenes (KRAS) and tumor suppressor 
genes (TP53). Furthermore, smoking appears to interact with genetic predispositions, 
including hereditary pancreatitis and familial PC, other strong risk factors for PC (43). 
 
3.1.2. Body fatness  
It has been suggested that the increase in obesity prevalence, as well as metabolism related 
diseases such as diabetes, could be partly responsible for the positive trends of PC, especially 
in Western countries (44). 
As a result, the relationship between excess body fatness and the risk of PC has been widely 
explored in cohort studies and several meta-analyses, which consistently have shown positive 
associations. Evidence from epidemiological studies was evaluated and considered as 
convincing by the WCRF/AICR expert panel and the association has been even more recently 
confirmed by the IARC monograph program (45,46). The body mass index (BMI), reflecting 
overall adiposity, is the most common measure evaluated in studies in relation to PC risk. 
Consistently in men and women, a continuous 5 kg/m² increase in BMI has been associated 
with a 10% to 18% increase in PC risk (46–48). Further, the specific role of central adiposity 
was evaluated through measures of both waist circumference (WC) and waist-to-hip ratio 
(WHR) in several studies, showing that a 10 cm increase in WC or a 0.1 increase in WHR 
were associated with 7% and 9% higher risks of PC, respectively (46,49–52). It has been 
suggested that the underlying mechanisms for the association with body fatness are driven by 
chronic inflammation due to remodeling of adipose tissue and ectopic lipid accumulation. 
Excess lipid storage in adipose tissue can lead to infiltration of lipids within muscle, liver and 
pancreatic tissue, and cause impairment of lipid processing and clearance within these tissues 
(53,54). Therefore, lipid intermediates impair the function of cells and increase the release of 
cytokines, which foster inflammation as well as insulin resistance (45). Recent findings from 
6 European cohorts showed that 42% of the relationship between BMI and PC risk was 
mediated by insulin resistance in men and women collectively, with a larger proportion 
mediated in women (91%) than men (20%) (55). It has been also suggested that the 
relationship between obesity and PC risk could be additionally mediated by adiponectin, an 
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inflammatory factors (56), especially among non-smokers (57), possibly suggesting common 
mechanism between obesity and tobacco smoking. 
The role of adult attained height in the occurrence of PC was also reported by the 
WCRF/AICR panel with probable evidence for a modest but significant positive association. 
Adult attained height might be a marker of genetic, environmental, hormonal and nutritional 
growth factors during growth (46). 
 
3.1.3. Physical activity  
Physical activity is believed to prevent PC by regulating body weight and decreasing insulin 
resistance (58), DNA damage (59), and chronic inflammation (60). Since practice of physical 
activity is a relatively easily modifiable lifestyle factor, it may offer possibilities for primary 
prevention of PC. Nonetheless, evidence for an association between physical activity and the 
risk of PC has been considered as limited and inconclusive in 2012 by the WCRF/AICR 
experts’ panel. The summary RR of high versus low total physical activity was of 0.74 
(95%CI: 0.55, 1.00) when based on a small number of studies (46,61). The statistical power in 
this study to assess consistency of results regarding the role of physical activity over time was 
insufficient, as well as the observed variation of the association by smoking status or level of 
obesity. A recent meta-analysis including 30 individual studies showed a weak but 
statistically significant inverse association for high versus low level of physical activity (RR: 
0.93, 95%CI: 0.88, 0.98), with strongest estimate for consistent level of physical activity over 
time (RR: 0.86, 95%CI: 0.76, 0.96, as compared with irregular past physical activity levels) 
(62). No evidence for variation by smoking status or BMI was found (62), while a recent 
evaluation in Asian population from the Shanghai Women and Men Health Studies showed a 
significant inverse association in men only (63). Despite rising recent epidemiological 
evidence and strong mechanistic hypotheses, the causal association between physical activity 
and PC risk is still not strongly supported by epidemiological evidence. Results need to be 
confirmed through interventional studies (62). 
 
3.1.4. Diet  
Despite the direct influence of diet energy imbalance on adiposity and evidence for the 
relationship between obesity and PC, epidemiological studies examining the association 
between any specific dietary patterns or food group and PC has been so far considered as 
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inconsistent and limited by the WCRF/AICR experts’ panel in 2012. However, since 2012 
several individual studies have provided evidence of positive associations with meat intakes 
(64), saturated fatty acids and industrial trans fatty acids (65), while whole grains (66), n-3 
polyunsaturated fatty acids (65) and low-fat dietary patterns (67) were inversely related to PC 
risk. These results were confirmed in a meta-analysis on the relation between dietary patterns 
and the risk of PC with a data driven approach, were associated with reduced risk of PC, 
where dietary patterns were characterized by high consumption of animal foods and 
associated nutrients, starch, or other typical Western type foods elevated PC risk, while 
dietary patterns rich in plant-based foods, whole grains, white meat, fiber, and associated 
antioxidants (68). A series of a priori diet scores have been also implemented to reflect 
adherence to specific dietary patterns, i.e. Mediterranean diet score, low inflammatory 
potential diet score, adherence to diet guidelines, and overall did not find significant inverse 
associations with PC (69–71). Overall, evidence of a relationship between diet and the risk of 
PC are so far inconsistent, perhaps due to several methodological limitations, including the 
lack of data from prospective studies and standardized methods to assess diet exposure. 
 
3.1.5. Alcohol  
The consumption of alcohol is one of the top-10 risk factors contributing to the worldwide 
burden of disease. Alcohol consumption is responsible for around 2.7 million annual deaths 
and 3.9% of the global burden of disease. Over the past four decades, per capita alcohol 
consumption has doubled in the United Kingdom and Denmark; during the same period, it has 
decreased by about one half in traditional wine-producing and wine-drinking countries such 
as Italy and France, and levels of consumption in these countries have converged. Alcohol 
consumption has increased steadily in Japan, China, and many other countries in Asia, where 
it was previously low, while trends have been constant in the United States (Figure 6) (72).  
There are several mechanisms through which alcohol is believed to promote cancer. 
Conversion of ethanol in acetaldehyde has a direct carcinogenic effect on the cells throughout 
the digestive tube where conversion occurs (73,74). Ethanol promotes production of highly 
reactive oxygen species, which can damage DNA, can alter DNA methylation, and has 
hormonal effects, including increasing estradiol levels (75). Furthermore, ethanol also 
facilitates uptake of other carcinogens (e.g. from tobacco smoking), thus also increasing the 
risk of tobacco-induced cancers. It may also propel already existing cancers through 
immunosuppression, and angiogenesis, and decrease the effect of chemotherapeutics (76). 
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Figure 6. Trends in recorded per capita alcohol consumption by adults in selected countries in 
the World (Source: Ezzati and Riboli, The New England Journal of Medicine, 2013)  
In 2012, the Monograph program at the International Agency for Research on Cancer (IARC) 
reviewed the available epidemiological evidence on the possible association between 
alcoholic beverage consumption and the risk of cancer at 27 anatomical sites, and reported 
that cancers of the upper digestive, liver, colorectum and breast are causally related to the 
consumption of alcoholic beverages. However, evidence regarding the risk of PC was 
considered as limited (77,78). Consecutively, the WCRF/AICR panel of experts also reviewed 
evidence for an association between alcohol drinking and PC as limited or suggestive as 
major part of evidence issued from case-control studies (46). In a more recent large meta-
analysis of 18 cohort studies, it was estimated that the association was restricted to heavy 
alcohol drinkers of more than 50 grams of ethanol per day (g/day) with an increased risk of 
PC by 19% when compared with nondrinkers or occasional drinkers (RR=1.19, 95%CI: 1.11, 
1.28) (79). Similar strengths of associations were observed more recently in a meta-analysis 
by Wang et al. with a 15% increasing risk of PC among individuals who drunk more than 24 
g/day (RR= 1.15, 95 CI: 1.06, 1.25) when compared with light drinkers of 0 to 12 g/day (80). 
These findings strengthen evidence of the associations observed for heavy alcohol use in prior 
pooled analyses (81–84). However, these previous studies had relatively limited statistical 
power to examine specific alcoholic beverages and effect modification by smoking status. 
Given that alcohol abuse is a cause of chronic pancreatitis, it has been proposed that excessive 
alcoholic intake could increase the risk of PC indirectly through this pathway (43). 
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3.2. Morbid conditions  
3.2.1. Diabetes  
The relationship between both type I and II diabetes and the risk of developing PC has been 
extensively evaluated over past decades and showed strong positive associations (85,86). PC 
burden attributable to diabetes has been evaluated to represent 10 to 16% of PC cases. 
Approximatively 80% of patients present an impaired glucose tolerance or a recent onset of 
type 2 diabetes at the moment of PC diagnosis (87). Indeed, due to the major role of the 
pancreas into glucose homeostasis, altered glucose metabolism may be a result of a 
progressive loss in pancreatic functions and reflect the tumor invasion. Therefore, type-2 
diabetes can be both a cause and a consequence of PC and experience a bidirectional 
association (88). 
More recent works have therefore focused on the evaluation of the duration between diabetes 
onset and PC diagnosis to account for potential reverse causation (89–91). Evidence 
suggested that overall long-term diabetes was associated with at 50% increased risk of PC 
(40), with PC risk decreasing with the duration of diabetes. A meta-analysis of 88 studies 
showed that RR for a duration of diabetes <1 year was 6.69 (95% CI: 3.80, 11.78), for a 
duration <5 years 1.86 (1.56, 2.21), for a duration <10 years 1.72 (1.47, 2.00), and after 10 
years RR was 1.36 (1.19, 1.55) (90). Another study showed that 30% excess risk persists for 
more than two decades after a diagnosis of diabetes (91).  
The underlying mechanisms potentially explaining this association combines a tumorigenic 
role of hyperglycemia, the mitogenic effect of hyperinsulinemia and chronic inflammation 
related to fat infiltration of the pancreas. This could be enhanced in the context of obesity 
related diabetes due to insulin resistance (89).  
 
3.2.2. Pancreatitis  
Pancreatitis is a condition characterized by inflammation of the pancreatic tissue. While acute 
pancreatitis occurs punctually under the influence of heavy alcohol drinking, gallstones 
formation, medication, or infection, chronic pancreatitis is a progressive and long standing 
inflammation of the pancreatic tissue leading to irreversible fibrosis and loss of pancreatic 
cells’ functions overtime (92). This chronic inflammation has been postulated to facilitate 
pancreatic cell progression to cancer (92). As for diabetes, the relation between pancreatitis 
and PC is bidirectional (88,93). 
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Both acute and chronic pancreatitis have been evaluated in association with PC risk in a 
pooled-analysis of 10 case-control studies from the international Pancreatic Cancer Case-
Control Consortium (PanC4). Pancreatitis diagnosed more than 2 years before PC diagnosis 
was associated with PC risk, with odds ratio (OR) equal to 2.71 (95% CI: 1.96–3.74), and OR 
was 13.56 (8.72–21.90) for pancreatitis occurring within less than 2 years before PC 
occurrence. Population attributable fraction was also estimated at 1.3% (95% CI: 0.61%, 
2.07%), suggesting that a relatively small proportion of PC could be avoided if pancreatitis 
could be prevented (94). Evaluations focusing on chronic pancreatitis showed stronger 
associations. A meta-analysis by Raimondi and colleagues suggested a strong association 
between chronic pancreatitis and PC with pooled RR of 13.3 (95%CI: 6.1, 28.9) (95). 
Nonetheless, chronic pancreatitis is a rare disease with an incidence rate ranging from 2 to 14 
cases per 100,000 PY. Additionally, less than 5% of PC cases occur among individuals with 
chronic pancreatitis (96). As heavy alcohol drinking is also a major cause of chronic 
pancreatitis, it has been suggested that alcohol consumption might be related to PC risk with 
chronic pancreatitis being the underlying mechanism between the two of them (7). 
 
3.2.3. Infectious diseases  
The associations between infections and occurrence of PC have been also investigated, 
including both bacterial and viral.  
Gastric colonization with Helicobacter pylori has been related with greater risk of PC. In a 
recent meta-analysis of 8 case-control studies, a pooled estimate showed a positive significant 
relationship between Helicobacter pylori infection and PC risk with a OR equal to 1.45 (95% 
CI: 1.09, 1.92). In a multi-center hospital-based American case-control study, the association 
has been examined with respect to Helicobacter pylori virulence protein phenotype CagA and 
showed significant increased risk of PC in relation to CagA-negative Helicobacter pylori 
seropositivity (OR: 1.68, 95% CI: 1.07, 2.66), but no association was observed for CagA 
seropositivity (OR: 0.77, 95% CI: 0.52, 1.16) (97). The association was more particularly 
restricted to individuals with non–O blood type with an OR equal to 2.78 (1.49, 5.20). It has 
been suggested that the presence of A or B blood group antigens might influence the 
properties of Helicobacter pylori binding (97). Although Helicobacter pylori prevalence varies 
widely across continent and countries, population attributable fraction of PC was estimated as 
great as 4-25% (40). Mechanisms involved in this relationship are still unknown. 
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Since the last decade, some studies have raised attention to the association between chronic 
infections such as hepatitis B and C viruses (HBV and HCV) and PC occurrence (15,87,98). 
An increasing amount of evidence from meta-analyses has indicated a positive association 
between active HBV and HCV infections and PC (99–102). However, so far evidence from 
observational studies are scarce, and require cautious interpretation regarding study design 
and definitions of infection status and PC cases (101). 
 
3.3. Genetic factors  
Several hereditary and genetic factors have been identified as possible cause of PC. PC 
occurring in people who do not carry a high risk genetic mutation, referred to as sporadic PC, 
represent 90% of cases. Only a small proportion (approximatively 5-10%) is thought to be 
explained by inherited forms like familial aggregations and high risk genetic syndromes 
(103), which includes hereditary pancreatitis, hereditary genetic syndromes and familial 
history of PC. The risk of PC related to such familial or genetic predisposition is considerably 
greater than in the general population and varies depending on the gene affected and 
concurrent lifestyle factors.  
Hereditary pancreatitis is a rare inflammatory disorder characterized by recurrent acute 
pancreatitis with a typical onset during childhood. It is caused by gain-of-function mutations 
in the cationic trypsinogen gene (PRSSI) (104,105). PRSS1 mutations result in the over-
activation of the trypsin, a digestive enzyme produced by the pancreas. Approximately 70% 
of pancreatitis result from the mutations R122H and N291 in the PRSS1 gene (105). At least 
half of the patients diagnosed with hereditary pancreatitis will develop chronic pancreatitis 
(106), and PC generally occurs about 30 years after the onset of chronic pancreatitis as a 
result of a prolonged trypsin related chronic inflammation. Compared with the general 
population, individuals with PRSSI mutations have been estimated to have 50 to 87 higher 
risk of PC than non-mutation carriers (107,108), while the risk of PC has been estimated to be 
between 54 and 154 higher in smokers who are also mutation carriers when compared to non-
smokers who are also non-mutation carriers (109).  
The risk of PC may be higher in subjects with hereditary genetic syndromes for who germ-
line mutations have been identified. Mutations occurring in tumor suppressor genes like 
STK11 gene (Peutz-Jeghers syndrome or PJS), CDKN2A gene (familial atypical malignant 
melanoma syndrome or FAMMM), BRCA1 and BRCA2 genes (hereditary breast and ovarian 
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cancer syndrome or HBOC) and APC gene (familial adenomatous polyposis or FAP 
syndrome) have been related to increase in risk ratio of PC ranging from 4 for HBCO 
syndrome to 132 in PJS as compared to the general population (104,105,110). Mutations in 
the mismatch repair genes MSH2 or MLH1 resulting in hereditary nonpolyposis colorectal 
cancer (HNPCC or Lynch syndrome) were associated with a cumulative risk of PC 9-time 
higher in older individuals. Mutation on the PALLD gene, encoding for control of cells shape 
and motility, was also recently related to site-specific familial PC, a familial syndrome with 
risk ratio ranging from 18-57 in comparison to general population. Additionally, KRAS, TP53 
and SMAD4 mutations have been suspected to occur in precursor lesion of sporadic forms of 
PC. Overall, whatever PC be sporadic or related to inherited syndromes, it has been estimated 
that around 1,000 genetic mutations occur during the pancreatic tumorogenesis (111). 
In the absence of known hereditary cancer syndrome related to a specific gene mutation, 
family history of PC has been established as a major risk factor of PC (104). Familial PC 
cases, defined as individuals with at least two first-degree relatives (parent, sibling or child) 
diagnosed with PC, is estimated to affect about 5-10% of PC cases (15). In a pooled analysies 
using data from nested case-control studies from the PanScan consortium, individual with a 
family history of PC with one first degree relative diagnosed with PC had an 80% increased 
risk of pancreatic adenocarcinoma (RR: 1.76, 95%CI: 1.19, 2.61) compared with individuals 
with no reported family history (112). 
The ABO blood group is also a genetically defined factor, which has been related to PC risk 
studies over the last decades. Recent meta-analyses and pooled prospective studies showed 
that the risk of developing PC was positively associated with non-O blood groups with 30–
40% higher risk of PC compared to individuals with the O blood group (40,113,114). In the 
PanScan consortium study, Wolpin and colleagues combined data from 12 prospective 
cohorts and showed that in comparison with subjects of O blood group, patients with blood 
group A, AB, and B had higher risk of PC with ORs equal to 1.38 (95%CI: 1.18, 1.62), 1.47 
(1.07,2.02), and 1.53 (1.21, 1.92), respectively (114). The mechanism by which the ABO 
blood group is involved in the occurrence of PC is not known, although it has been suggested 
that the alteration of the ABO glycosyltransferase activity, an enzyme which might be 
involved in PC carcinogenesis, mainly by aﬀecting cell proliferation, tumor invasion and 
metastatic spread (115). 
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4. Challenges of pancreatic cancer for epidemiological studies  
PC etiology has been extensively investigated. Although genetic factors are well identified, 
they offer the potential to understand only a small proportion of PC cases occurring 
worldwide. Besides, epidemiological investigations have led to the identification of a limited 
number of modifiable lifestyle factors for which there are strong evidence for causal 
relationships with PC occurrence, including tobacco smoking and body fatness. Evaluations 
of the role of alcohol consumption, level of physical activity or diet have been so far limited 
or inconclusive and offer limited room for the implementation of primary prevention policies. 
PC is a rare cancer which has been mostly investigated in case-control studies, widely subject 
to recall bias and selection bias. Potential true causal relationship between lifestyle risk 
factors and PC, if they exist, are likely to be weak. Therefore, the most favorable context to 
investigate such relationship should allow a large-scale prospective examination and have a 
long follow-up of participants to have a sufficiently large number of cases to detect an 
association.  
 
5. Thesis objectives  
The main objective of this PhD program was to investigate the etiology of PC by 
strengthening epidemiological evidence on the role of alcohol consumption and more 
generally the role of a combination of lifestyle factors in relation to PC incidence. For this 
purpose, evidence from the ongoing multicenter prospective cohort study, the European 
Prospective Investigation into Cancer and nutrition (EPIC) study, was used. 
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1. Context and objectives  
The European Prospective Investigation on Cancer and Nutrition (EPIC) study was initiated 
in the 1990’s at the International Agency for Research on Cancer (IARC), based on the 
limited success in identifying links between diet and cancer through experimental and case-
control studies, and the necessity to investigate prospectively at a large scale the occurrence of 
cancer in relation to diet and lifestyle (116). The project started with a series of pilot studies to 
evaluate the methodology for the establishment of a very large prospective cohort with the 
collection and storage of blood samples and the feasibility of recruiting participants (117).  
The principal goal of the EPIC study was to investigate the etiology and the incidence of 
cancers, as well as many kinds of chronic diseases, in relation to diet, lifestyle and 
environmental factors taking advantage of the contrast in cancer rates and dietary habits 
between centers and countries and of the large overall size of the study. 
 
2. Study population  
From 1992 to 2000, 521,324 participants were recruited in 23 centers across 10 European 
countries including Spain, Italy, France, the United Kingdom, Greece, Germany, Netherlands, 
Denmark, Sweden, and Norway (Figure 7), and have been followed-up for more than 15 
years. To date, the EPIC study represents one of the largest ongoing multicenter prospective 
studies worldwide. 
 
Figure 7. Countries and centers involved in the EPIC study (Source: IARC/WHO) 
43 
 
EPIC participants were recruited in the general population, of which 70% are women, aged 
from 35 to 70 years. Exceptions were the French cohort (school and university employees), 
the Spanish and Italian centers (blood donors), Utrecht and Florence centers (breast cancer 
screening participants), and Oxford (vegetarians and ‘health conscious’ participants). In 
France, Norway, Utrecht and Naples women only were recruited. Study participants provided 
informed consent before completing questionnaires at baseline. At baseline, all of the cohort 
members signed an informed consent form. Approval for this study was obtained from the 
relevant ethical review boards of the participating institutions (116). 
 
3. Ascertainment of outcomes  
Cancer cases were identified during follow-up based on population cancer registries in 
Denmark, Italy, Netherlands, Norway, Spain, Sweden, and the United Kingdom, and on a 
combination of methods, including health insurance records, contacts with cancer and 
pathology registries, and active follow-up of EPIC participants and their next of kin in France, 
Germany, and Greece. Mortality data were collected from, either the cancer or mortality 
registries at the regional or national level. 
The most recent vital status and cancer diagnosis are known for 98.4% of all EPIC subjects, 
while 1.6% of participants emigrated, withdrew or were lost to follow-up. The current follow-
up period ended as follows: December 2009 in Varese and Murcia, December 2010 in 
Florence, Ragusa, Turin, Asturias, Bilthoven and Utrecht, December 2011 in Granada, 
Navarra, San Sebastian and Cambridge, December 2012 in Oxford, Umeå, Norway and 
Denmark, and December 2013 in Malmö. The end of follow-up was considered as the last 
known contact with participants in France (June 2008), Heidelberg and Potsdam (December 
2009), and Naples (December 2010) and Greece (December 2012).  
In the present work, cases of PC were identified as primary incident tumor of the pancreas. 
They were coded according to the International Classification of Diseases (10th edition), and 
included all invasive PC (C25.0–C25.3, C25.7–C25.9). Because of they have different 
prognosis, endocrine and neuroendocrine tumors of the pancreas (C25.4), as well as carcinoid 
tumors (8240/3) and lymphoma (9591/3) were censored at date of diagnosis (n=54). As result, 
there was 1,283 PC cases identified within a median follow-up of 15 years in the EPIC study. 
Microscopically confirmed PC represented 83% of the cases (n=928) based on histology of 
the primary tumor or metastases, cytology or autopsy reports.  
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4. Diet and lifestyle assessment  
Information on habitual diet and alcohol intakes over the year preceding recruitment was 
assessed at recruitment by validated centre-/country- specific dietary questionnaires designed 
to capture local-dietary habits with high compliance (116,117). To calibrate dietary 
measurements, a standardized computer-assisted 24-hour dietary recall was implemented at a 
center level on stratified random samples of the participants, for a total of 36,900 subjects and 
used as a reference method to correct for systematic between-centre over- or underestimations 
in the baseline dietary assessments (118).  
Anthropometric measurements were performed (self-reported in France, Norway and the UK 
Oxford centre) (119,120) to collect information on height, weight, waist circumference and 
hip circumference. Occupational and physical activities, education, prevalent chronic 
conditions (hypertension, diabetes, cardio-vascular diseases), lifetime history of tobacco 
smoking, lifetime alcohol intake and menstrual and reproductive history (including the use of 
exogenous hormones for contraception and post-menopausal replacement therapy) were 
collected through lifestyle questionnaires.  
Follow-up measures of diet and lifestyle exposures have been collected in about 70% of the 
centers. The centralization and harmonization are currently ongoing at IARC and data should 
be available in 2020. 
 
5. Biobank, blood samples collection  
Blood samples were collected at baseline from 387 889 individuals (88%). Plasma, serum, 
leukocytes, and erythrocytes have been separated and aliquoted for long-term storage in liquid 
nitrogen at IARC and mirrored at EPIC collaborating centers. Overall, the EPIC 
biorepositories host more than 9 million aliquots, constituting one of the largest biobanks in 
the world for biochemical and genetic investigations on cancer and other chronic diseases. 
that can integrate questionnaire data on lifestyle and diet, biomarkers of diet and of 
endogenous metabolism (e.g. hormones and growth factors) and genetic polymorphisms. 
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1. Background  
PC is one of the most fatal cancers worldwide (17,26). Its etiology has been extensively 
researched, leading to the identification of tobacco smoking, body fatness, type-II diabetes 
mellitus and chronic pancreatitis as major risk factors (23,40,46,98). Although alcohol 
consumption has been recognized as a type 1 carcinogen by IARC Monograph, the evidence 
for an association between alcohol use and the risk of PC has been considered as suggestive 
and limited by international experts panels (46,77). Studies examining the association of PC 
risk with smoking status, type of alcoholic beverages and drinking history have been limited 
by the small number of cases in prospective studies as PC remains a particularly rare cancer 
(17). 
Previous prospective studies yielded evidence for an excess risk of PC limited to high levels 
of alcohol consumption (81,121–123). Recent meta analyses have shown that alcohol intake 
increased the risk of PC by at least 15% in drinkers consuming more than 25 g/day compared 
with light drinkers with alcohol intake below 12g/day (79,80). The vast majority of these 
investigations has primarily focused on baseline alcohol intake, though two early analyses 
from the EPIC study indicated that neither baseline nor cumulative lifetime alcohol intake 
were related to PC risk (124,125). In addition, heavy drinking is a risk factor for chronic 
pancreatitis, a condition posited to be involved in the underlying mechanisms of PC (126). It 
has been hypothesized that the relationship between alcohol and PC could be entirely 
explained by occurrence of chronic pancreatitis (127). 
In this study, the association between alcohol intake and the risk of PC was comprehensively 
investigated using information from the EPIC study and involving a larger number of incident 
PC cases than earlier evaluations. 
 
2. Objectives  
- To investigate the role of past alcohol consumption examining lifetime alcohol intake 
in relation to PC risk. 
- To evaluate the potential differences in the relationship according to the type of 
alcoholic beverages consumed. 
- To investigate the role of smoking habits in the relationship between alcohol 
consumption and PC risk, especially in non-smokers. 
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- To evaluate the potential role of chronic pancreatitis in the relationship between 
alcohol intake and PC risk. 
 
3. Methods  
This study was carried out using information from the EPIC cohort (128). After 15 years of 
follow-up, 1,283 incident PC cases were diagnosed from 521,324 cancer-free participants. 
Baseline alcohol intake was assessed through dietary questionnaire (116,117) and computed 
from the number of glasses of beer and/or cider, wine, sweet liquors and/or distilled spirits 
and fortified wines drunk per day or week during the 12 months preceding recruitment. 
Lifetime alcohol consumption was measured as the number of glasses from the different types 
of beverages consumed per week at 20, 30, 40 and 50 years of age. It was assessed from a 
lifestyle questionnaire and was available for 76% of study participants corresponding to 966 
PC cases over 363,265 participants. 
Cox proportional hazard models with age as primary time variable were used to estimate PC 
hazard ratios (HR) and 95% confidence intervals (CI). Separate models were run by gender to 
account for the behavioural differences in alcohol intake between men and women. Baseline 
and lifetime alcohol intakes were modeled as continuous variables, with HR estimates for a 12 
g/day increase in alcohol intake (corresponding to a standard drink of beer, spirits/liquors, or 
wine) and in categories (<0.1 g/day, 0.1–4.9, 5–14.9, 15–29.9, 30–59.9 and >60), using the 
group of light drinkers (0.1-4.9 g/day) as reference. Dose–response analyses were performed 
for baseline and lifetime alcohol intake in men and in all participants together. Potential 
departures from linearity in the associations were examined by fitting restricted cubic spline 
models (129). Effect modification in the relationship between alcohol and PC risk by smoking 
status (never, current smokers) was evaluated by comparing models with and without 
interaction terms.  
In the absence of information on chronic pancreatitis in EPIC, a sensitivity analysis was 
carried out to account for the potential role of chronic pancreatitis (Z) between baseline 
alcohol intake (X) and risk of PC (D) using information from the literature (130). In EPIC, 
HR estimate for the risk of PC in baseline heavy drinkers (>60g/day) compared to light 
drinkers (0.1-4.9g/day) was equal to 1.64 (95% CI: 1.22, 2.21) in men and women combined. 
PC HRs for heavy drinkers vs. light drinkers considering information on chronic pancreatitis 
(HRDX) were estimated assuming values from the literature for pancreatitis prevalence among 
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moderate drinkers ranging from 0.005 to 0.02 (131), relative risk estimates of chronic 
pancreatitis in relation to alcohol intake greater than 25 g/day compared to the never drinkers 
(RRZX) ranging from 2 to 6 (131,132), and relative risk estimates of PC associated with 
chronic pancreatitis (RRDZ) ranging from 1.5 to 15 (94,95,126). 
 
4. Results  
In men, baseline alcohol intake was significantly associated with PC risk, with a 5% (95% CI: 
1%, 9%) increased PC risk for every increment of 12 g/day of alcohol. HR for men heavy 
drinkers with more than 60 g/day of alcohol was 1.63 (95%CI: 1.16, 2.29). No evidence for an 
association between alcohol and PC risk was found in women. Similar observations were 
found for lifetime alcohol intake. In men, a 12 g/day increase of lifetime alcohol intake was 
related to a 6% (2%, 10%) increased PC risk, with a HR for heavy drinkers (>60 g/day) equal 
to 1.77 (1.06, 2.95) when compared to the reference category. No statistically significant 
association between lifetime alcohol intake and PC risk was found in women. In evaluations 
by types of alcoholic beverages, beer consumption was positively associated with a 9% (2%, 
15%) and a 22% (3%, 44%) increase in PC risk for 12 g/day in men and women, respectively. 
In men, spirits/liquors were associated with a 17% (4%, 32%) higher PC risk for a 12 g/day 
increase, while no association was observed in women. Wine intake was not associated with 
PC risk irrespective of sex. Similar results were observed for lifetime alcohol intake from the 
different beverages and PC risk.  
Evaluation of the dose response relationship between baseline and lifetime alcohol intake and 
PC risk in men suggested a linear shaped association, without evidence for departure from 
linearity either for baseline (pnon-linearity=0.83) or lifetime intakes (pnon-linearity=0.57). Similar 
results were found when examining all participants, with p-values for non-linearity equal to 
0.90 and 0.75 for baseline and lifetime intakes, respectively (Figure 8).  
Although alcohol intake was not associated with PC risk among never smokers (HR per 12 
g/day increase: 1.06; 95% CI: 0.98, 1.15), current smokers had a HR equal to 1.05 (1.00, 
1.11). There was no evidence for heterogeneity between alcohol and PC risk with respect to 
smoking statuses (pheterog= 0.84). 
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Figure 8. Hazard Ratio (HR) functions (and 95% CI) describing the curvilinear dose–
response relationship between baseline and lifetime alcohol intake (g/day) and PC risk, 
according to the frequency of cases in all participants. 
 
The sensitivity analysis using information from the litterature about history of chronic 
pancreatitis indicated that the HR estimate comparing baseline heavy drinkers (>60 g/day) vs. 
light drinkers (0.1-4.9 g/day) was marginally attenuated when considering realistic scenarios 
with a prevalence of chronic pancreatitis in moderate drinkers of 0.01, with a relative risk 
estimate for the relation between alcohol and chronic pancreatitis as large as 4, and a PC 
relative risk associated with chronic pancreatitis not exceeding 10. Larger attenuations of HR 
estimates were observed for more extreme scenarios showing weaker positive HRDX 
estimated (Figure 9). Findings suggested that alcohol intake may exert its carcinogenic role 
only partially through chronic pancreatitis. Studies with individual data on history of 
pancreatitis may allow for a more advanced mechanistic approach to estimate the proportion 
of alcohol-PC association mediated by pancreatitis. 
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Figure 9. Sensitivity analysis using external information from the scientific literature on 
history of chronic pancreatitis (Z), in the relationship between baseline alcohol intake (X) and 
the risk of pancreatic cancer (D). 
 
5. Conclusions  
In summary, our study showed a moderate but statistically significant increase in PC risk with 
high alcohol intake, either baseline or lifetime, and particularly for beer and spirits/ liquors. 
These findings provide epidemiologic evidence for the role of alcohol consumption as a 
potential carcinogen of the pancreas. 
 
6. Scientific article 
“Lifetime and baseline alcohol intakes and risk of pancreatic cancer in the European 
Prospective Investigation into Cancer and Nutrition study”, Naudin S et al., International 
Journal of Cancer, Published, March 2018. 
Roles of the PhD student: 1st author, participated to the analytical strategy, conducted all 
analyses, wrote the manuscript, revised and submitted it. 
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1. Background  
Commonly diagnosed at late stages, PC is a highly fatal cancer with limited opportunities for 
effective treatment (17,35). In the current absence of available screening tools, the 
identification of modifiable risk factors may offer opportunities for PC primary prevention. 
Examinations of lifestyle risk factors with respect to PC incidence in prospective studies have 
led to the identification of smoking, body fatness, adult attained height, type-2 diabetes, and 
heavy alcohol drinking as positive risk factors, while diet and physical activity have been 
inconsistently associated with PC risk (40,46). Although lifestyle habits often cluster together 
(133), there is limited evidence regarding the joint association of different lifestyle factors on 
PC incidence, especially among European populations.  
A multi-component score termed the Healthy Lifestyle Index (HLI), combining information 
on smoking, alcohol intake, dietary habits, body mass index (BMI), and physical activity has 
been previously related to several cancers sites in the European Prospective Investigation into 
Cancer and Nutrition (EPIC) study (134–137). Within the American Association of Retired 
Persons (AARP) cohort a strong inverse association was observed between the HLI and PC 
risk (138). So far, evidence for an inverse association in European population has been 
limited to an evaluation from an Italian case-control study (139). 
 
2. Objectives  
- To examine the relationship between the HLI and PC risk within the EPIC study using 
two versions of the score: (i) with BMI to reflect overall adiposity and (ii) with waist-
to-hip ratio to reflect central adiposity. 
- To investigate the marginal role of each single lifestyle factors of the HLI score in 
association with PC risk, particularly for smoking. 
- To estimate population attributable fractions based on counterfactual and realistic 
scenari where study participants adopted healthier behaviors. 
- To examine the pattern of the association between the HLI and PC incidence over 
age. 
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3. Methods  
This study was carried out using information from the EPIC cohort. After 15 years of follow-
up, 1,283 incident PC cases were diagnosed from 521,324 cancer-free participants. The HLI 
score was generated from the combination of information on smoking history, alcohol intake, 
a dietary score, BMI, and physical activity, with larger values indicating adherence to 
healthier habits (137). Since previous evidence on PC etiology identified waist-to-hip ratio 
(WHR), an indicator of central adiposity, as a PC risk factor (50,140), a HLI based on the 
WHR (HLIWHR) was computed replacing BMI categories with sex-specific WHR quintiles 
(Figure 10). Subjects with missing information on smoking status (n=15,684) and physical 
activity (n=65,054) were excluded. For analyses with HLIWHR, subjects with missing WHR 
were also excluded (n=45,105). The final study population included 400,577 participants of 
which 1,113 PC cases in analyses with HLIBMI, and 1,075 cases in analyses with HLIWHR. 
 
 
Figure 10. Scoring system combining the 5 lifestyle factors into the Heathy Lifestyle Index 
based on the waist-to-hip ratio (HLIWHR).   
1 For the HLI based on the BMI (HLIBMI), sex-specific waist-to-hip ratio quintiles were 
replaced by categories of BMI at baseline using the following cut-offs: (4) 22–23.9 kg.m-2, 
(3) 24–25.9 kg.m-2, (2) <22 kg.m-2, (1) 26–29.9 kg.m-2, and (0) >30 kg.m-2 
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Cox proportional hazard models with age as primary time variable were used to estimate PC 
hazard ratios (HR) and their 95% confidence intervals (CI). The HLIBMI and HLIWHR were, in 
turn, modeled as continuous variables computing HR estimates for a one-standard deviation 
(1-SD) increase in the HLI score corresponding to approximatively 3 units, and in categories 
(0-4, 5-9, 10-14, 15-20), using the group 5-9 as reference. All models were stratified by study 
center, sex and age at recruitment. Models were adjusted for education level, diabetes status, 
energy intake from non-alcohol sources, and height was undertaken, and additionally for BMI 
in models with HLIWHR.  
Sensitivity analyses were carried out by excluding, in turn, each factor from the HLI scores to 
identify which factors are driving the HLI association with PC risk. The excluded component 
was used as a confounder in the model. 
Population attributable fractions (PAF) were estimated as the reduction in PC incidence that 
would occur (i) if study participants shifted to the adjacent healthier category of HLIWHR, and 
(ii) assuming a counterfactual scenario whereby men adopted women’s lifestyle habits (141). 
Confidence intervals were obtained using bootstrap sampling (142). 
The pattern of HR for a 1-SD increase of HLIWHR by age was examined using a flexible 
parametric survival model on the cumulative hazard scale. Restricted cubic splines with 5 
internal knots were used to model the baseline hazard using attained age as the time scale and 
a time-varying coefficient on HLIWHR (143). 
 
4. Results  
HR estimates for PC risk given for a one-standard deviation increment of HLIBMI and 
HLIWHR were equal to 0.84 (95% CI: 0.79, 0.89; ptrend=4.3e-09) and 0.77 (0.72, 0.82; 
ptrend=1.7e-15), respectively. Exclusions of, in turn, smoking, alcohol and WHR from HLIWHR 
resulted in HRs of 0.88 (0.82, 0.94; ptrend=4.9e-04), 0.79 (0.74, 0.84; ptrend=7.0e-13), and 0.79 
(0.74, 0.85; ptrend=3.2e-11), respectively. PAF based on counterfactual scenari where 
participants adopted healthier behaviors indicated that controlling obesity, alcohol 
consumption, having a healthy diet and improving physical activity could prevent no less 
than 14% (95% CI: 6%, 21%) of PC cases, and up to 19% (11%, 26%) if quitting smoking 
was also considered. Interestingly, 13% (9%, 16%) of PC cases would be prevented if men 
adopted lifestyle habits of women. Examination of PC HR estimates pattern for a 1-SD of 
HLIWHR showed weaker associations at older ages. 
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5. Conclusions  
In this large European prospective study, healthy lifestyle habits expressed in a HLI score 
were strongly inversely related to the risk of PC. Adherence to healthy behaviors 
corresponding to a three-point increase in the score was associated with a 16% (95%CI: 11%, 
21%) lower PC risk for a score that included BMI, and 23% (18%, 28%) lower PC risk for a 
score including WHR. Our findings provided evidence that adherence to healthy lifestyle 
habits could be an effective primary prevention strategy to control the incidence of PC. 
 
6. Scientific article  
“The Healthy lifestyle and the risk of pancreatic cancer in the EPIC study”, Naudin et al., 
European Journal of Epidemiology, Published, September 2019. 
Roles of the PhD student: 1st author, participated to the analytical strategy, conducted all 
analyses, wrote the manuscript, revised and submitted it. 
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1. The Pooling Project on Alcohol and Cancer  
As part of this PhD program, I had the opportunity to take part to the Pooling Project on 
Alcohol and Cancer (PPAC), a large ongoing study aiming at the evaluation of the association 
between alcohol consumption and cancer sites for which the relationship with alcohol is not 
established within prospective studies participating to the National Cancer Institute (NCI) 
Cohort Consortium. This project was initiated as a collaborative project coordinated by IARC 
(Principal investigators (PI): Drs. Pietro Ferrari and Paul Brennan) and the Harvard School of 
Public Health (Co-PI: Dr. Stephanie Smith-Warner). In 2016, the project was successfully 
granted by the National Institute on Alcohol Abuse and Alcoholism (NI-AAA). The following 
part will provide an overview of the ongoing work with this project and what was 
accomplished as part of the PhD program. 
 
1.1. Background and significance  
In 2012, the IARC Monograph program defined alcohol consumption as causally related to 
the incidence of several cancer sites including cancers of the upper aero-digestive tract 
(UADT), liver, colorectal and female breast cancers, as confirmed by the WCRF/AICR 
experts’ panels in 2012 (77,144). Whereas the association of these specific cancer sites with 
alcohol use has been consistently observed, the evidence of the link with other cancers, 
primarily prostate and pancreatic, but also kidney, thyroid cancer and non-Hodgkin 
lymphoma (NHL) was either inconsistent or sparse (79). Despite the importance in human 
carcinogenesis, several research questions on alcohol and cancer remain far to be answered.  
The relationship between alcohol use and cancer sites with an established link with alcohol 
was recently confirmed in the EPIC study with respect to cancer incidence (145) and overall 
and cancer-specific mortality (146), both for baseline and lifetime alcohol uses (147). 
Lifetime alcohol use was also significantly associated with mortality from the ensemble of 
non-alcohol related cancer sites (147), suggesting a potential role of alcohol for cancer sites 
other than those evaluated by the IARC Monograph program (77). It has been observed more 
recently in pooled studies and meta-analyses that alcohol use was positively associated with 
risk of PC (84) and prostate cancer (79). Also there is suggestive evidence for an inverse 
association between alcohol use and the risk of cancer of the kidney (148), thyroid (79), and 
NHL (149,150). However, scientific evidence on these associations is still very inconsistent 
and unclear regarding plausible biological mechanisms involved.  
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The evaluation of the relationship between alcohol and cancer presents several analytical 
challenges. First, if a relationship between alcohol and any of these cancer sites existed, it 
would likely be weak; thus, requiring a large sample size to have sufficient statistical power to 
detect associations. Second, many of the cancer sites investigated in the PPAC are fairly rare 
cancers, in particular for PC and NHL (in women) and thyroid cancer (in men). Any 
epidemiological investigation would require information from large study population, with a 
long follow-up in order to develop a sufficiently large number of cancer cases. This scenario 
is likely to materialize through a collaborative effort to pool data from ongoing large 
prospective epidemiological investigations, as in the PPAC consortium. 
 
1.2. Objectives  
The global aim of the PPAC project is to conduct a pooled analysis of 36 prospective studies 
on the role of alcohol use and the risk of cancer sites for which the evidence is suggestive or 
limited, namely: prostate, pancreas, UADT, kidney, thyroid, and NHL. The evaluation will 
particularly focus on the following specific objectives:  
- To evaluate the associations between alcohol consumption and cancers of the prostate, 
pancreas, kidney and UADT in non-smokers 
- To evaluate associations of lifetime alcohol use (assessed in 7 studies) with risk of 
advanced and localized prostate, pancreatic, kidney, and thyroid cancer, and NHL 
- To evaluate specific patterns of alcohol use, including binge drinking (assessed in 11 
studies), in relation to risk of advanced and localized prostate, pancreas, kidney, and 
thyroid cancer, and NHL. 
This project will produce solid evidence on the role of alcohol on the aforementioned cancer 
sites for which the relationship with alcohol is not established, thus allowing an update of the 
burden of cancer attributable to alcohol use in different populations across the world.  
 
1.3. Study design  
Individual-level data from 36 cohort studies spanning 4 continents (American, Europe, Asia 
and Oceania) including over 2.7 million women and men were centralized and will be 
evaluated in the coming year. The Table 1 provides the list of the studies involved in the 
project. Information about alcohol intake (including past consumption, intake at recruitment, 
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and intake during follow-up), dietary intake and lifestyle covariates is collected through food 
frequency questionnaires, lifestyle questionnaires and questionnaire during follow-up within 
each individual study is centralized at Harvard. The follow-up of participants will start at the 
date of completion of the baseline questionnaire for the exposure of interest and last until the 
date of death, date of lost-to-follow-up, or administrative end date, whichever occurred first. 
Cancer outcomes considered in this project are primary invasive cancers of the prostate, the 
pancreas, the kidney, the thyroid, UADT cancers and NHL. At the beginning of the study it 
was expected to reach over 161,000 incident cases with 4,800 thyroid cancer; 9,900 kidney 
cancer, and more than 10,000 each for pancreatic, UADT and prostate cancer, and NHL. 
 
1.4. Data centralization and harmonization  
Centralization and harmonization of primary participant level data originating from the 36 
studies involved in the project was initiated in 2017, and are still ongoing. These steps 
benefits from expertise and data already collected by Harvard collaborators few years ago as 
part of a previous long-standing international consortium called the Pooling Project of 
Prospective Studies of Diet and Cancer (DCPP) which included 26 cohorts.  
Data centralization started with the implementation of a list of variables that were requested to 
all participating studies of the PPAC. For this purpose, I developed the dictionary providing 
definitions for variables on mortality, end of follow-up, cancer outcomes, covariates collected 
at baseline and during follow-up (including lifestyle, dietary and medical history), and on 
alcohol exposure (including information about alcohol intakes at baseline, during lifetime and 
during follow-up) (Annex 1). The principal investigators of each cohort were contacted to 
require a list of variables in August 2017. The 26 cohorts already involved in the DCPP 
received a shorten list focusing on variables on alcohol consumption and on update of cancer 
outcomes. Data were centralized by Harvard scientists, and were remotely accessible from 
IARC using a secured server.  
A second part of my contribution was to harmonize information on of cancer outcomes across 
participating cohorts. The task started during the summer 2018 based on data already 
centralized at that time. Under the supervision of an IARC pathologist, cancer site-specific 
criteria of inclusion and exclusion were defined. Cancer sites considered in this project were 
cancer of the prostate (C61), the pancreas (C25.0, C25.1, C25.2, C25.3, C25.7, C25.8, C25.9), 
the kidney (C64), the thyroid (C73) and UADT (C00, C01, C02, C03, C04, C05, C06, C09, 
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C10, C11, C13, C14, C15.0, C15.1, C15.3, C15.8, C15.9) based on the International 
Classification of Diseases (ICD) 10th edition (Table 2). Criteria were refined at the 
histological and morphological level using the ICD-Oncology (ICD-O) 3rd edition coding 
system. The exhaustive list of histological and morphological type is provided in Table 2. As 
the classification for NHL outcomes has changed several time over the last decades due to 
their biologically and clinically changing definition (151,152), the participating cohorts might 
have used different versions of the ICD-O classification to define the histology of their NHL 
cases. As a result, I produced a separate table summarizing for each subtype of lymphoma the 
corresponding histology codes providing equivalence between the different IDC-O versions 
(Annex 1). 
The harmonization of the data collected on alcohol intake is currently ongoing (Table 1). 
Next steps of the project will be to analyze participant-level data from each cohort using 
uniform criteria across studies and control for key covariates (e.g., smoking habits) to provide 
the most complete and reliable information for the evaluation of these associations between 
alcohol use and the targeted cancer- sites.  
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2. Lifestyle factors in association with the risk of lymphoma  
While the various steps of the PPAC were implemented, including data centralization and 
harmonization, interest emerged on the examination within the EPIC study of the relationship 
between alcohol and risk of several cancer sites that were the target of the PPAC. The 
association between alcohol intake and lymphoma had not been investigated in EPIC yet, 
mainly due the limited number of lymphoma cases, particularly by subtypes. Statistical 
analyses were therefore undertaken as part of this PhD program. Results showed weak 
associations for baseline alcohol intake, with HR for non-Hodgkin lymphoma (NHL) and for 
Hodgkin lymphoma (HL) equal to 1.00 (95% CI: 0.98, 1.03) and 0.85 (0.74, 0.99), 
respectively, for a 12 g/day increase in alcohol intake. Similar risk patterns were observed for 
lifetime alcohol intake, overall and by lymphoma subtypes. The investigation was also 
extended to a larger list of lifestyle factors, through the HLI score, and the risk of lymphoma 
in EPIC. 
 
2.1. Background  
Lymphoma is a heterogeneous group of malignancies occurring in the lymphatic system with 
biologically and clinically diverse definitions depending on immune cells involved in the 
carcinogenic process. Traditionally, they are grouped in Hodgkin (HL) and non-Hodgkin 
lymphoma (NHL). NHL is divided into two major subtypes, mature T and natural killer-cell 
lymphoma (MT/NK) and mature B-cell lymphoma (BCL), with BCL subdivided by diffuse 
large B-cell lymphoma (DLBCL), follicular lymphoma (FL), chronic lymphocytic leukemia 
and small lymphocytic leukemia (CLL/SLL), and plasma cell neoplasm and multiple 
myeloma (PCN/MM) (152). In 2018, lymphoma accounted for 3.2% of incident cancers 
worldwide, and their incidence steadily increased over the past decades, particularly in high-
incomes countries (17,153). Additionally, a large part of the increase in incidence is still 
poorly understood and the role of lifestyle exposure in lymphomagenesis remains particularly 
unclear (154). Although individual lifestyle factors have been related to the risk of lymphoma 
(149,155), there is limited evidence regarding the joint association of lifestyle factors on the 
risk of lymphoma. In this work, the association between adherence to healthy lifestyles and 
risks of HL and NHL was evaluated in a large European prospective study. 
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2.2. Methods  
Within the European Prospective investigation into Cancer and Nutrition (EPIC) study 2,659 
incident lymphoma cases, including 120 HL and 2,446 NHL, were diagnosed from 400,622 
cancer-free participants after 14 years of follow-up. The healthy lifestyle index (HLI) score 
combined information on the history of smoking, alcohol intake, diet, the level of physical 
activity and BMI, with large values of HLI expressing adherence to healthy behaviors. Cox 
proportional hazards models with age as primary time variable were used to estimate 
lymphoma hazard ratios (HR) and their 95% confidence interval (CI). Models were stratified 
by sex, country and age at recruitment, and adjusted for education level, height, and energy 
intake from non-alcohol sources. The HLI was modeled in continuous for a 1-SD increase in 
the HLI (around 3 units) and in quartiles using the second quartile as the reference category. 
Sensitivity analyses were conducted by excluding, in turn, each lifestyle factor from the HLI 
score. 
 
2.3. Results  
Our results showed an inverse association between the HLI and the risk of HL, with HR for a 
1-SD increment in the score equal to 0.81 (95%CI: 0.68, 0.97). Sensitivity analyses showed 
that the association was mainly driven by smoking, and marginally by diet and BMI.  
Overall lymphoma and NHL were not associated with HLI, with HRs for a 1-SD increment 
equal to 0.99 (0.96, 1.03) and 1.00 (0.96, 1.04), respectively.  
There was no association in evaluations by NHL subtypes. HR estimates comparing the fourth 
to the second quartile were equal to 0.93 (95%CI: 0.81, 1.06; ptrend=0.40) for BCL,1.31 (1.00, 
1.74; ptrend=0.25) for DLBCL, 1.01 (0.90, 1.13; ptrend=0.62) for FL, 1.02 (0.93, 1.12; 
ptrend=0.62) for CLL/SLL, and 0.98 (0.90, 1.06; ptrend=0.61) for PCN/MM. Although, the EPIC 
study benefits from a large sample size, this evaluation was possibly underpowered to detect 
likely weak associations in analysis by subtypes of NHL. 
 
2.4. Conclusions  
In the EPIC study, adherence to healthy lifestyle was not associated with overall lymphoma or 
NHL risks. An inverse association was observed for HL, although it was largely attributable 
to smoking. Overall, these findings suggested a limited role of lifestyle factors in the etiology 
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of lymphoma subtypes. However, this study is one of the first attempts to investigate the risk 
of lymphoma with respect to healthy lifestyle habits, and results should be replicated in other 
studies. 
 
2.5. Short communication  
“Healthy lifestyle and the risk of lymphoma in the EPIC study”, Naudin et al., Under revision, 
International Journal of Cancer, November 2019. 
Roles of the PhD student: 1st author, participated to the analytical strategy, conducted all 
analyses, wrote the manuscript, and revised it. 
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GENERAL CONCLUSION  
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1. Main findings  
Commonly diagnosed at late stage, PC is a highly fatal cancer with limited opportunities for 
early detection and effective treatment. In this context, the identification of modifiable risk 
factors may contribute to PC prevention. This doctoral research program intended to enhance 
the understanding of PC etiology, focusing on the role of alcohol consumption and more 
globally on lifestyle determinants. 
Our overall findings showed a moderate but significant positive association with high alcohol 
intake. Evaluation of the dose-response relationship suggested a linear alcohol- PC 
association. Consistent results were observed using information on alcohol intake at baseline 
and alcohol consumed during the life course. Examination by type of alcoholic beverages 
showed positive relationships with beer and spirits/liquors, and a weaker association with 
wine. Although the relationship was weaker in never than in current smokers and no 
association was observed in women, there was no statistically significant evidence for 
heterogeneity by smoking status or by gender, potentially pointing to limitations regarding 
subgroup analyses in the evaluation of rare disease. A sensitivity analysis accounting for the 
role of chronic pancreatitis showed evidence for a moderate mediating role of chronic 
pancreatitis. If alcohol is causally related to PC risk, it is likely to only partly involve 
pancreatitis mechanism. 
The second evaluation undertaken during this PhD resulted in strong evidence for an inverse 
relationship between healthy lifestyle habits and PC occurrence, using a score combining 
information on smoking history, alcohol intake, obesity, diet and physical activity. The 
evaluation suggested a marginally stronger association with a score considering information 
on central adiposity rather than overall adiposity. Our results pointed to associations being 
marginally stronger at younger ages. Estimated population attributable fractions suggested 
that controlling obesity, alcohol consumption, diet quality and increasing the level of physical 
activity could prevent 14% of PC cases, and up to 19% if quitting smoking was also 
considered. Interestingly, 13% of PC cases could be prevented if men adopted lifestyle habits 
of women. Overall, although a large proportion of PC cases is still unexplained, these findings 
provide evidence that realistic changes in common lifestyle habits could sizably decrease the 
risk of PC. 
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2. Perspectives  
With respect to the work undertaken during this PhD program, future research aiming at 
improving the understanding of PC etiology through investigation of alcohol consumption 
and lifestyle factors should consider the following challenges. 
While our findings strengthen the epidemiological evidence for the relationship between 
alcohol use and PC risk, future research steps should focus on the clarification of the 
association among specific populations. In the current work, the evaluation was hampered by 
the low number of cases in nonsmokers and women, who are also less likely to be heavy 
drinkers. As PC remains of low incidence, it is likely that the collective effort of prospective 
investigations will be required to provide a sufficiently large number of cancer cases to 
conduct an accurate investigation of the association among these subgroups. Future 
evaluations should benefit from the strong framework provided by consortia of prospective 
studies within the NCI cohort consortium, and in particular the Pooling Project on Alcohol 
and Cancer. 
Since extreme alcohol intake is a cause of chronic pancreatitis, it has been suggested that 
alcohol intake could increase PC risk through this pathway. Findings from our first 
evaluation, based on a sensitivity analysis using information on the link between pancreatitis 
and PC risk extracted from the scientific literature, suggested that the relationship between 
alcohol and PC could be moderately attenuated. Although there is a strong association 
between individuals with chronic pancreatitis and the risk of PC compared with the general 
population (95), the proportion of PC arising from patients with chronic pancreatitis is very 
low (131). The use of mediation analysis in studies where the information on the history of 
pancreatitis was collected could clarify to what extent the alcohol-PC association is mediated 
by chronic pancreatitis and provide a better understanding about whether the carcinogenic 
role of alcohol on PC is dependent from the pancreatitis mechanism. 
Our second evaluation provided strong evidence for an inverse relationship between healthy 
lifestyle habits and the risk of PC. Notably, we estimated that 13% of PC cases could have 
been avoided if men adopted similar lifestyle habits as women. This proportion partially 
explains the difference in PC incidence in men (Europe ASR=5.5 per 100,000 PY) compared 
with women (Europe ASR=4.0 per 100,000 PY), although other elements are to be considered 
to explain the remaining difference. Our study used a healthy lifestyle score implemented on 
the basis of a priori general knowledge on the relationship between lifestyle factors and risk 
of chronic diseases, and was not specific to PC. Yet, it has the advantage of producing 
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evidence comparable across different cancer sites. Given the difference in smoking habits in 
men and women, the use of weights to combine the various components of the score may 
have provided results more specific to PC. Also, the score could have included other factors 
related to cancer, e.g. information on infectious diseases and morbid conditions (type-2 
diabetes, hypertension), which might have contributed to explain more accurately the gender 
difference. Lastly, as pancreatic carcinogenesis has a genetic origin, information on genetic 
profiles could also have provided key elements to elucidate the gap between men and women. 
Our findings on lifestyle habits were based on European populations and yielded similar 
evidence on the strong relationship between lifestyle habits and PC as in an American 
investigation in the NIH-AARP cohort (138). This evidence needs to be confirmed in other 
populations, possibly characterized by diverse lifestyle habits in different geographical 
contexts. 
Socio-economic status is believed to play a major role in the occurrence of PC (156,157) and 
some of the components of the HLI may act as mediators of this association (158). The 
relationships observed in our study between healthy lifestyle habits and the risk of PC could 
possibly provide a partial overview of the causal pathway between socio-economic status and 
PC risk. Additionally, other lifestyle factors not included in the HLI could be on the same 
pathway. As a result, socio-economic status is an important confounder of the HLI-PC 
association, and our analyses were consistently adjusted for participants’ level of education, 
although the use of education as a proxy for socio-economic status may have produced 
residual confounding. 
Our studies considered lifestyle and dietary information collected at recruitment among adult 
participants. However, within 15 years of follow-up, individuals may have modified their 
lifestyle habits, possibly leading to different findings. Thanks to the collaboration between the 
EPIC participating centers and IARC, data on lifestyle and dietary factors collected during 
follow-up will soon be available. Examination of serial questionnaire information collected on 
alcohol intake and lifestyle factors will enable future studies to consider potential changes in 
alcohol intake and lifestyle habits in relation to the risk of PC, and further complete the work 
initiated during this PhD. 
Furthermore, information on potential mechanisms related to the role of alcohol and a 
combination of lifestyle factors on pancreatic carcinogenesis are far from being identified. 
Metabolomics data could be instrumental for the investigation of pathological processes and 
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could notably enhance the understanding of the mechanisms of alcohol–related pancreatic 
carcinogenesis (159). 
This comprehensive evaluation provides informative insights on the role of alcohol 
consumption and healthy lifestyle habits in the etiology of PC. It strongly supports the 
development of effective primary prevention strategy and the implementation of public health 
guidelines to promote the adoption of healthy lifestyle habits for the sake of PC prevention. 
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Variable List for Alcohol and Cancer Project 
for New Studies in the Diet and Cancer Pooling Project 
August, 2017 
 
- Cohort name 
- Study Center, if applicable 
- Country 
- Region of the country 
- Participant ID code 
- Personal history of cancer at baseline 
 
Mortality and end of follow-up data 
- Date of administrative end of follow-up 
- Age at end of follow-up (years; please include decimals, if possible) 
- Death status (yes, no) 
- Date of death 
- Age at death (years; please include decimals, if possible) 
- ICD code for underlying cause of death 
- ICD version 
- Date of loss to follow-up 
- Age lost to follow-up (years; please include decimals, if possible) 
 
Cancer outcomes (only first primary, invasive incident tumors are of interest) 
- Date of diagnosis of any cancer (if you cannot provide the date, please provide the year of cancer 
diagnosis, if possible) 
- Age at diagnosis of any cancer (years; please include decimals, if possible)  
**This information is instrumental to censor study participants’ follow-up time in statistical analyses 
on each cancer site detailed below. 
 
Kidney cancer  
Body-site ICD9Dx-CM codes ICD10Dx-CM codes 
Kidney, except pelvis  189.0 C64.-  
 
- Kidney cancer case status (yes, no) 
- Date of diagnosis of kidney cancer (if you cannot provide the date, please provide the year of 
kidney cancer diagnosis, if possible) 
- Age at diagnosis of kidney cancer (years; please include decimals, if possible)  
- Location of the tumor (ICD code) 
- ICD version 
- Stage of cancer (In situ, localized, metastatic, metastatic regional, metastatic distant, unknown) 
- TNM classification 
- Version of TNM classification 
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- Behavior of the tumor (carcinoma in situ, malignant primary site, metastatic, benign) 
- Morphology of the tumor 
- Grade of the tumor (undifferentiated, poorly, moderately, well or not differentiated) 
 
Pancreatic cancer  
Body-site ICD9Dx-CM codes ICD10Dx-CM codes 
Head of pancreas  157 C25.0  
Body of pancreas 157.1 C25.1  
Tail of pancreas  157.2 C25.2  
Pancreatic duct  157.3 C25.3  
Other specified sites of pancreas  157.8 C25.7  
Other specified sites of pancreas  157.8 C25.8  
Pancreas, part unspecified  157.9 C25.9  
 
- Pancreatic cancer case status (yes, no) 
- Date of diagnosis of pancreatic cancer (if you cannot provide the date, please provide the year of 
pancreatic cancer diagnosis, if possible) 
- Age at diagnosis of pancreatic cancer (years; please include decimals, if possible) 
- Location of the tumor (ICD code) 
- ICD version 
- Stage of cancer (In situ, localized, metastatic, metastatic regional, metastatic distant, unknown) 
- TNM classification 
- Version of TNM classification 
- Behavior of the tumor (carcinoma in situ, malignant primary site, metastatic, benign) 
- Morphology of the tumor 
- Grade of the tumor (undifferentiated, poorly, moderately, well or not differentiated) 
 
Thyroid cancer  
Body-site ICD9Dx-CM codes ICD10Dx-CM codes 
Malignant neoplasm of thyroid gland  193 C73 
 
- Thyroid cancer case status (yes, no) 
- Date of diagnosis of thyroid cancer (if you cannot provide the date, please provide the year of 
thyroid cancer diagnosis, if possible) 
- Age at diagnosis of thyroid cancer (years; please include decimals, if possible) 
- Location of the tumor (ICD code) 
- ICD version 
- Stage of cancer (In situ, localized, metastatic, metastatic regional, metastatic distant, unknown) 
- TNM classification 
- Version of TNM classification 
- Behavior of the tumor (carcinoma in situ, malignant primary site, metastatic, benign) 
- Morphology of the tumor 
- Grade of the tumor (undifferentiated, poorly, moderately, well or not differentiated) 
 Annexe 1, page 148 
 
- Methodology of diagnosis 
 
Upper aero-digestive tract (UADT) cancer 
Body-site ICD9Dx-CM codes ICD10Dx-CM codes 
Malignant neoplasm of lip (inner aspect) 140.3, 140.4, 140.5 C00.3, C00.4, C00.5 
Malignant neoplasm of tongue 141 to 141.9 
C01.x, C02.0, C02.1, C02.2, 
C02.3, C02.4, C02.8, C02.9 
Malignant neoplasm of gum 143, 143.0, 143.1, 143.8, 143.9 C03, C03.0, C03.1, C03.9 
Malignant neoplasm of floor of mouth 144, 144.0, 144.1, 144.8, 144.9 
C04, C04.0, C04.1, C04.8, 
C04.9 
Malignant neoplasm of other and unspecified 
parts of mouth 
145 to 145.9 
C05, C05.0, C05.1, C05.2, 
C05.8, C05.9, C06, C06.0, 
C06.1, C06.2, C06.8, C06.9 
Malignant neoplasm of oropharynx and tonsils 146 to 146.9 
C10.0, C10.1, C10.2, C10.3, 
C10.4, C10.8, C10.9, C09.0, 
C09.1, C09.8, C09.9 
Malignant neoplasm of nasopharynx 
147, 147.0, 147.1, 147.2, 147.3, 
147.8, 147.9 
C11.0, C11.1, C11.2,C11.3, 
C11.8, C11.9 
Malignant neoplasm of hypopharynx 
148, 148.0, 148.1, 148.2, 148.3, 
148.8, 148.9 
C13.0, C13.1, C13.2, C13.8, 
C13.9 
Malignant neoplasm of other and ill-defined sites 
within the lip oral cavity and pharynx 
149, 149.0, 149.1, 149.8, 149.9 C14, C14.0, C14.2, C14.8 
Malignant neoplasm of nasal cavities middle ear 
and accessory sinuses 
160, 160.0, 160.1, 160.2, 160.3, 
160.4, 160.5, 160.8, 160.9 
C30.0, C30.1, C31.0, C31.1, 
C31.2, C31.3, C31.9, C31.9 
Malignant neoplasm of larynx 
161, 161.0, 161.1, 161.2, 161.3, 
161.8, 161.9 
C32.0, C32.1, C32.2, C32.3, 
C32.8, C32.9 
Malignant neoplasm of oesophagus 
150.0, 150.1, 150.2, 150.3, 150.4, 
150.5, 150.8, 150.9 
C15.0, C15.1, C15.2, C15.3, 
C15.4, C15.5, C15.8, C15.9. 
 
 
- UADT cancer case status (yes, no) 
- Date of diagnosis of UADT cancer (if you cannot provide the date, please provide the year of 
UADT cancer diagnosis, if possible) 
- Age at diagnosis of UADT cancer (years; please include decimals, if possible) 
- Upper aero digestive tract site (ICD code) 
- ICD version 
- Stage of cancer (In situ, localized, metastatic, metastatic regional, metastatic distant, unknown) 
- TNM classification 
- Version of TNM classification 
- Behavior of the tumor (carcinoma in situ, malignant primary site, metastatic, benign) 
- Morphology of the tumor 
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- Grade of the tumor (undifferentiated, poorly, moderately, well or not differentiated) 
 
Non-Hodgkin lymphoma (NHL)  
 Eligible codes, by coding scheme† 
Site ICD9Dx-CM codes ICD10Dx-CM codes ICD-O-3 codes‡ 
Non-Hodgkin 
lymphoma (NHL) 
or 
Lymphoid neoplasm 
(LN) 
Codes 202.0, 202.1, 202.2, 
202.4, 202.7, 202.8, 202.9, 207.8 
and 273.3. 
Codes and “child codes” 
beginning with 200, 203 and 
204. 
Code C96.Z. 
Codes and “child codes” 
beginning with C82, C83, 
C84, C85, C86, C88, C90 
and C91. 
9590 to 9597, 
9670 to 9729, 
9731 to 9738, 
9761, 9764, 9766, 
9811 to 9837, 
9940, 9948, 9970 
† For more detailed list that include the names of individual conditions, see Appendix table on InterLymph 
Hierarchical Classification for Lymphoid Neoplasms and correspondences for ICD-O-3, ICD-9 and ICD-10 
codes.  
‡ All site codes are allowable; report site code and cell lineage (B, T, NK) if available.  
 
- Non-Hodgkin lymphoma (NHL) case status (yes, no)  
- Date of diagnosis of NHL (if you cannot provide the date, please provide the year of NHL 
diagnosis, if possible) 
- Age at diagnosis of NHL (years; please include decimals, if possible) 
- Cell type (B, T, NK, unknown)  
- Nodal or extranodal  
o If extranodal, please specify site(s) and/or ICD-O-3 site (topography) code if possible 
- Provisional subtype classification (Diffuse large B-cell, follicular, etc.) 
- Classification system for subtype (WHO, REAL, Working formulation etc.) 
- Histology type code (ICD-O-2 or -3 if possible) or diagnosis code (ICD-9 etc.) 
- Classification used for histology or diagnosis, and version (ICD-O-2, ICD-O-3, ICD-9, etc.) 
- Stage of cancer (In situ, localized, metastatic, metastatic regional, metastatic distant, unknown)  
o Indications of extranodality (“E”), A/B symptoms and/or bulk (“X”) if available 
- Staging method used (Ann Arbor or other [please specify]) 
- Grade of the tumor (undifferentiated, poorly, moderately, well or not differentiated) if 
available/applicable 
- International Prognostic Index (IPI), if available; 
- For follicular lymphoma cases, in addition to above items, 
o "FLIPI" if available 
- For chronic lymphocytic leukemia (CLL) cases,  
o Year of diagnosis of CLL 
o Month and day of CLL diagnosis, if possible 
o Age at diagnosis of CLL (years; please include decimals, if possible) 
o B or T cell type, if known 
o Histology type code (ICD-O-2 or -3 codes if possible; specify which type code is 
provided) or diagnosis code (specify ICD-9, -10 etc.) 
o Rai stage, if known 
o Binet stage, if known 
 
Prostate cancer  
Body-site ICD9Dx-CM codes ICD10Dx-CM codes 
Malignant neoplasm of prostate 185 C61  
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- Prostate cancer case status (yes, no) 
- Date of prostate cancer diagnosis (if you cannot provide the date, please provide the year of 
prostate cancer diagnosis, if possible)  
- Age at prostate cancer diagnosis (years; please include decimals, if possible) 
- Location of the tumor (ICD code) 
- ICD version  
- Stage of disease and staging method used. We would prefer to receive separate data on 
1) Primary tumor (T), Regional lymph nodes (N) and Distant metastases (M), and the version 
of TNM classification used 
2) or SEER extent of disease code (if available), the name of the manual(s), and the version 
used 
- Behavior of the tumor (carcinoma in situ, malignant primary site, metastatic, benign) 
- Morphology of the tumor 
- Grade of the tumor (undifferentiated, poorly, moderately, well or not differentiated) 
- Gleason score 
- Primary and secondary Gleason pattern scores separately, if available 
- PSA at diagnosis, if available 
- Diagnosed during a screening process (Yes, No) 
 
Covariate data collected at baseline 
 
General and lifestyle covariates 
- Date the baseline questionnaire was returned 
- Age at baseline questionnaire return (please include decimals if possible) 
- Date of birth 
- Gender 
- Race  
- Educational level 
- Marital status 
- Weight 
- Height  
- Waist circumference 
- Hip circumference 
- Body weight at age 18/20 years or young adulthood 
- Physical activity:  
Since this information has been asked in a variety of ways across studies, we would like to 
create a physical activity variable with three categories: ‘sedentary’, ‘moderate activity’ 
and ‘vigorous activity’. If you have already created a variable for physical activity 
reflecting these levels, we would like the derived variable and an explanation of how the 
variable was derived, in addition to the raw data. Otherwise, please send us the data that 
you currently have available for analyzing physical activity.   
- Smoking:  
For all smoking variables, separate information for cigarettes, pipes, and cigars would be 
useful, if available 
o Smoking status (never, former, current) 
o Smoking pack-years  
o Age at which smoking was initiated 
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o Age at which smoking ceased  
o Time since quitting smoking 
o Duration of smoking  
o Amount smoked 
o Passive smoking  
- Non-steroidal anti-inflammatory drug use 
- Personal history of hypertension 
- Treatment for hypertension 
- Age at menarche, women only 
- Parity, women only 
- Age at first birth, women only 
- Menopausal status, women only 
o Yes, No 
o Age at menopause 
o Type of menopause 
- Hormone replacement therapy use (never, former, current), women only 
- Oral contraceptive use (never, former, current), women only 
- Latitude 
- Family history of pancreatic cancer 
- Family history of thyroid cancer 
- Family history of kidney cancer 
- Family history of lymphoma 
- Family history of prostate cancer 
- Family history of upper aero-digestive tract (UADT) cancer 
- Personal history of pancreatitis  
o Yes, No, Unknown 
o Type of pancreatitis: Acute, Chronic, Other type, Unknown 
- Diabetes status (Yes, No, Unknown) 
- Type of diabetes 
- Personal history of benign thyroid diseases 
- Multivitamin use  
o Yes, no 
o Number of multivitamins per day 
o Duration of use 
 
Dietary covariates 
- Date the baseline dietary questionnaire was returned 
- Age at dietary questionnaire return, if different from age at baseline questionnaire return (please 
include decimals if possible) 
- Energy intake (Calories/day) 
- Energy intake excluding alcohol drinking (Calories/day) 
- Protein (g/day) 
- Carbohydrates (g/day) 
- Total fat (g/day) 
- Saturated fat (g/day) 
- Monounsaturated fat (g/day) 
- Polyunsaturated fat (g/day) 
- Cholesterol (mg/day) 
- Dietary fiber (g/day) 
- Vitamin B6 from food sources only (mg/day) 
- Vitamin B6 from foods plus supplements (mg/day) 
- Vitamin B12 from food sources only (ucg/day) 
- Vitamin B12 from foods plus supplements (ucg/day) 
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- Folate from foods (ucg/day) 
- Folate from foods plus supplements (ucg/day) 
- Methionine (g/day) 
- Incomplete or not usable dietary questionnaire (yes, no); (we will exclude participants from 
analyses involving dietary variables other than alcohol consumption)  
 
Covariate data collected during follow-up  
Please create separate variables for information coming from each follow-up cycle and mention for 
each of them:  
- Date of follow-up questionnaire 
- Age at follow-up questionnaire return (please include decimals if possible) 
- Duration covered by the follow-up questionnaire (1 year, 1 month, 1week, other). 
 
General and lifestyle covariates 
- Weight 
- Height  
- Waist circumference 
- Hip circumference 
- Physical activity:  
Since this information has been asked in a variety of ways across studies, we would like to 
create a physical activity variable with three categories: ‘sedentary’, ‘moderate activity’ 
and ‘vigorous activity’. If you have already created a variable for physical activity 
reflecting these levels, we would like the derived variable and an explanation of how the 
variable was derived, in addition to the raw data. Otherwise, please send us the data that 
you currently have available for analyzing physical activity.   
- Smoking:  
For all smoking variables, separate information for cigarettes, pipes, and cigars would be 
useful, if available 
o Smoking status (never, former, current) 
o Smoking pack-years  
o Age at which smoking ceased  
o Time since quitting smoking 
o Duration of smoking  
o Amount smoked 
o Passive smoking  
- Non-steroidal anti-inflammatory drug use 
- Personal history of hypertension 
- Treatment for hypertension 
- Parity, women only 
- Age at first birth, women only 
- Menopausal status, women only 
o Yes, No 
o Age at menopause 
o Type of menopause 
- Hormone replacement therapy use (never, former, current), women only 
- Oral contraceptive use (never, former, current), women only 
- Family history of pancreatic cancer  
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- Family history of thyroid cancer 
- Family history of kidney cancer 
- Family history of lymphoma 
- Family history of prostate cancer 
- Family history of upper aero-digestive tract (UADT) cancer 
- Personal history of pancreatitis  
o Yes, No, Unknown 
o Type of pancreatitis: Acute, Chronic, Other type, Unknown 
- Personal history of diabetes 
- Diabetes status (Yes, No, Unknown) 
- Type of diabetes 
- Personal history of benign thyroid diseases 
- Multivitamin use  
o Yes, no 
o Number of multivitamins per day 
o Duration of use 
 
Dietary covariates 
- Date the follow-up dietary questionnaire was returned 
- Age at follow-up dietary questionnaire return (please include decimals if possible) 
- Energy intake (Calories/day) 
- Energy intake excluding alcohol drinking (Calories/day) 
- Protein (g/day) 
- Carbohydrates (g/day) 
- Total fat (g/day) 
- Saturated fat (g/day) 
- Monounsaturated fat (g/day) 
- Polyunsaturated fat (g/day) 
- Cholesterol (mg/day) 
- Dietary fiber (g/day) 
- Vitamin B6 from food sources only (mg/day) 
- Vitamin B6 from foods plus supplements (mg/day) 
- Vitamin B12 from food sources only (ucg/day) 
- Vitamin B12 from foods plus supplements (ucg/day) 
- Folate from foods (ucg/day) 
- Folate from foods plus supplements (ucg/day) 
- Methionine (g/day) 
- Incomplete or not usable dietary questionnaire (yes, no); (we will exclude participants from 
analyses involving dietary variables other than alcohol consumption)  
 
Alcohol exposure data 
 
Baseline alcohol information 
- Baseline alcohol intake (g/d) 
- Baseline alcohol intake from beer (g/d) 
- Baseline alcohol intake from wine (g/d) 
- Baseline alcohol intake from liquors/spirits (g/d) 
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Lifetime alcohol information 
Please provide details on the assessment method.  
- Lifetime total alcohol intake (g/d) 
- Did lifetime include baseline alcohol (yes, no) 
- Lifetime alcohol intake from beer (g/d) 
- Lifetime alcohol intake from wine (g/d) 
- Lifetime alcohol intake from liquors/spirits (g/d) 
- Alcohol intake (g/d) during different life periods if available, also providing the ages 
corresponding to the different life periods 
o Alcohol at age-i (g/d) 
- Information on drinking patterns 
o Number of days per week that alcohol was consumed (day(s)) 
o Number of alcohol drinks consumed on a day (when alcohol is consumed) (glass(es)) 
o How often a large number of drinks is consumed on a single day 
- Information on binge drinking 
Please, give details on the assessment method if other variables were used. 
o Binge drinking (yes, no, unknown)  
o Number of drink(s) usually consumed per drinking occasion 
- Former drinking  
o Age started drinking alcohol (year) 
o Age stopped drinking alcohol (year) 
- Former drinker of beer (yes, no) 
o Age started drinking alcohol from beer (year) 
o Age stopped drinking alcohol from beer (year) 
- Former drinker of wine (yes, no) 
o Age started drinking alcohol from wine (year) 
o Age stopped drinking alcohol from wine (year) 
- Former drinker of spirits and liquors (yes, no) 
o Age started drinking alcohol from spirits and liquors (year) 
o Age stopped drinking alcohol from spirits and liquors (year) 
 
Alcohol intake during follow-up 
Please create separate variables for each follow-up cycle and mention for each of them: 
- year of follow-up questionnaire 
- duration covered by the follow-up questionnaire (1 year, 1 month, 1week, other) 
- Alcohol intake during follow-up (g/d) 
- Alcohol intake from beer during follow-up (g/d) 
- Alcohol intake from wine during follow-up (g/d) 
- Alcohol intake from liquor during follow-up (g/d) 
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